Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Clinical trial NCT04588922 · RECRUITING
Trial details
- NCT number
- NCT04588922
- Sponsor
- Sellas Life Sciences Group
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-10
- Primary completion
- 2026-12-30
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.